TRML Tourmaline Bio, Inc. Common Stock

XNAS 47.98 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

TRML $47.98 —
Key stats
$47.98
52-Week Range
$47.98 – $48.00
IV Rank (30D)
0.21
Straddle Price
$1.60
P/C Vol Ratio
0.40
Market Cap
$1.2B
Open
$47.98
Day Range
$47.98 – $48.00
Volume
783,730
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$1.2B
Employees
77
List Date
2023-10-19
CIK
0001827506
Headquarters
New York, NY
Homepage
https://www.tourmalinebio.com

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patie…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
Insufficient price history — listed 1104 days ago. Seasonality patterns need at least one full year of data.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $47.90
SMA 50: $40.68
SMA 200: $22.74
Current: $47.98
EMA 12: $47.86
EMA 26: $46.23
MACD: 1.6316 | Signal: -0.6161
BULLISH
ADX (14): 81.22
STRONG TREND
+DI: 58.85
−DI: 5.09

Momentum Oscillators

RSI (14): 89.34
OVERBOUGHT
Stoch %K: 85.96
Stoch %D: 83.08
Williams %R: -10.53

Volume & Volatility

BB Upper: $47.99
BB Lower: $47.82
NEUTRAL
OBV: 26,158,109
Vol SMA 20: 653,257
Vol ROC: 213.94%
ATR: $0.28
True Range: $0.02
HV 20: 2.6%
HV 30: 3.4%
HV 60: 99.2%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2023-10-30T00:00:00 – 2025-10-27T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary Overall Assessment: BULLISH (Confidence Level: 8/10) Key Drivers: * Strong technical signals from MACD and RSI * Low volatility, indicating a stable market environment Primary Risks: * Potential for profit taking after recent gains Recent News Sentiment Impact: * Neutral news sentiment overall, with no major bearish or bullish catalysts

Technical Analysis Trend Direction: Short-term (1-4 weeks) - Uptrend; Medium-term (1-3 months) - Uptrend; Long-term (3-12 months) - Bullish Support/Resistance Levels: * SMA 20: $47.90 (support) * EMA 26: $46.23 (resistance) Momentum Signals: * RSI (14): 89.34 (overbought) * MACD: 1.63 / Signal: -0.62 / Histogram: 2.25 (bullish) Volume Analysis: * Volume SMA 20: 653257.70 * On-Balance Volume (OBV): 26158109.00

News & Sentiment Analysis Recent Headlines Summary: * Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum (NEUTRAL) * Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025 (NEUTRAL) Sentiment Assessment: NEUTRAL Catalyst Identification: * None major catalysts identified Market Narrative: Technical signals remain strong, with no clear contradicting news sentiment

Risk & Volatility Assessment Beta Interpretation: Low risk relative to market (beta <0.8) Volatility Regime: Current vs historical volatility levels - low Options Market Signals: * IV Rank: 3.2% (Low) * Put/Call Volume Ratio: 0.40 (Bullish sentiment)

Market Context & Positioning Sector Performance: Relative strength within sector/market Institutional Activity: Institutional interest signals present Correlation Analysis: Stock moves relatively less than market (R-squared <0.2) Relative Valuation: Position within trading range

Key Levels & Action Items Critical Price Levels: * SMA 20: $47.90 (support) * EMA 26: $46.23 (resistance) Breakout/Breakdown Levels: * None identified Time-Sensitive Catalysts: * Earnings dates, FDA approvals, product launches Risk Management: * Stop-loss levels and position sizing considerations

Additional Insights

The stock's recent price action is characterized by a strong uptrend, supported by technical indicators like the MACD and RSI. The low volatility environment and bullish sentiment from options market signals further reinforce this assessment.

However, there are some risks to consider: * Potential for profit taking after recent gains * Low news sentiment impact on current price action

Overall, I recommend a BULLISH stance with a confidence level of 8/10. The stock's technical and fundamental characteristics suggest continued upward momentum, but traders should remain cautious due to the potential for profit taking or market volatility shifts.

Generated
Earnings History
7 of 7 under expected move
Avg Expected Move
21.84%
Avg Actual Move
3.28%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-03-19 Pre-Market 35.62% 0.80% 0.02x Within
2024-05-13 Pre-Market 24.69% 0.41% 0.02x Within
2024-08-08 After-Close 16.33% 3.92% 0.24x Within
2024-11-07 Pre-Market 17.61% 0.95% 0.05x Within
2025-03-13 Pre-Market 20.28% 4.73% 0.23x Within
2025-05-02 Pre-Market 21.01% 8.68% 0.41x Within
2025-08-13 Pre-Market 17.34% 3.45% 0.20x Within

Earnings calendar: this week’s reports with expected vs actual moves →

TRML Options Activity & IV Rank

TRML IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 17.5%
7-DTE IV: —
Expected Move: $1.60
7-DTE Move: $1.60
Days to Exp: 25 (2025-11-21)

Options Flow

Call Volume: 10
Put Volume: 4
P/C Volume: 0.4
BULLISH
Call OI: 54
Put OI: 64
P/C OI: 1.185
Total OI: 118

ATM Options Pricing

ATM Call: $0.38
ATM Put: $1.23
Call %: 0.8%
Put %: 2.6%

Chain Summary

Chain Volume: 1,333
Chain OI: 4,887
Last Updated: 10/27/2025
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 6th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
6%
vs own history
GEX tilt
-0.36
OI-weighted, today
Vanna tilt
+1.00
δ-sensitivity to IV
Charm tilt
-1.00
δ-decay vs time
Vanna tilt +1.00: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -1.00: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 4 ATM contracts, 1k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 27 · No data
30 DTE / 10d —
+6.2 pts EXTREME
as of Oct 27 · ATM 11.6% / Wing 17.8%

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)0.2LowOct 27
Straddle Price (30 DTE)$1.60Oct 27
Beta Analysis
Insufficient price history — listed 1104 days ago. Beta and correlation vs SPY require ~1 year of daily returns to be statistically meaningful.

TRML Institutional Ownership (13F)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

# Filer Shares Value % of Total % of Float Period
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

TRML Insider Trading (Form 4)

Latest: 2025-10-28
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2025-10-28 Caley Castelein Director U −947,936 — EDGAR
2025-10-28 Mark McDade Director U −742,209 — EDGAR
2025-10-28 W Bradford Middlekauff CBO, GC and Secretary Mixed −69,201 — EDGAR
2025-10-28 Sapna Srivastava Director U −518 — EDGAR
2025-10-28 Susan Dana Jones Chief Technology Officer Mixed −22,934 — EDGAR
2025-10-28 Clay B Siegall Director Disp (D) −51,800 opt — EDGAR
2025-10-28 Parvinder Thiara Director U −83,782 — EDGAR
2025-10-28 Aaron Kantoff Director U −88,281 — EDGAR
2025-10-28 Ryan F. Robinson CFO U −14,366 — EDGAR
2025-10-28 Sandeep Chidambar Kulkarni CEO Mixed −762,051 — EDGAR
2025-10-28 Kevin Bruce Johnson Chief Regulatory Officer Mixed −51,584 — EDGAR
2025-10-24 Ryan F. Robinson CFO Exer (M) +14,366 $13.92 $200.0K EDGAR
2025-10-24 Aaron Kantoff Director Gift (G) −5,000 — EDGAR
2025-10-24 Sandeep Chidambar Kulkarni CEO Exer (M) +25,316 $7.90 $200.0K EDGAR
2025-10-17 Kevin Bruce Johnson Chief Regulatory Officer Gift (G) −6,250 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

TRML Insider Holdings

2 insiders · @ $47.98
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Sandeep Chidambar Kulkarni CEO 30,387 $1.46M $277.3K 7 2025-10-28
2 W Bradford Middlekauff CBO, GC and Secretary 8,213 $394.1K $0 2 2025-10-28
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

TRML Board & Officers

As of SEC filings through Oct 28, 2025

10% owners 1

Changes in the last 10 years (81)
Oct 28, 2025W Bradford Middlekauff reported in an SEC filing no longer being CBO, GC and Secretary
Oct 28, 2025Susan Dana Jones reported in an SEC filing no longer being Chief Technology Officer
Oct 28, 2025Sapna Srivastava reported in an SEC filing no longer being a director
Oct 28, 2025Sandeep Chidambar Kulkarni reported in an SEC filing no longer being a director
Oct 28, 2025Sandeep Chidambar Kulkarni reported in an SEC filing no longer being CEO
Oct 28, 2025Ryan F. Robinson reported in an SEC filing no longer being Chief Financial Officer
Oct 28, 2025Parvinder Thiara reported in an SEC filing no longer being a director
Oct 28, 2025Novartis Ag became a 10% owner
Oct 28, 2025Mark McDade reported in an SEC filing no longer being a director
Oct 28, 2025Kevin Bruce Johnson reported in an SEC filing no longer being Chief Regulatory Officer
Oct 28, 2025Clay B Siegall reported in an SEC filing no longer being a director
Oct 28, 2025Caley Castelein reported in an SEC filing no longer being a director
Oct 28, 2025Aaron Kantoff reported in an SEC filing no longer being a director
Oct 4, 2024The company announced the departure of Yung H. Chyung as Chief Medical Officer in an SEC filing
Jun 27, 2024Ryan F. Robinson listed as Chief Financial Officer (previously Interim CFO) in SEC filings
Dec 13, 2023Clay B Siegall became a director
Nov 29, 2023The company announced the departure of Cariad Chester from the board in an SEC filing
Oct 19, 2023Yung H. Chyung became Chief Medical Officer
Oct 19, 2023W Bradford Middlekauff became CBO, GC and Secretary
Oct 19, 2023The company announced the departure of Suzanne Ildstad from the board in an SEC filing
Not reported recently (29)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

TRML Proposed Insider Sales (Form 144)

Latest: 2023-07-05
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2023-07-05 Requadt Scott Former Officer and Director 11,786 $36.3K 2023-07-05 Fidelity Brokerage Services LLC — EDGAR
2023-07-05 Fenton Mary Kay Officer 12,946 $39.9K 2023-07-05 Fidelity Brokerage Services LLC — EDGAR
2023-06-01 SUZANNE ILDSTAD Director 250,000 $662.5K 2023-06-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2023-04-21 Suzanne Ildstad Officer 10,051 $24.0K 2023-04-21 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-3.44
TTM Revenue
—
TTM Net Income
$-88.47M
TTM Op. Cash Flow
$-86.28M
Quarterly figures (7 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '252025-06-30—$-23.09M$-0.90$-20.26M
Q1 '252025-03-31—$-22.97M$-0.89$-21.68M
Q4 '242024-12-31—$-22.23M$-0.87$-20.89M
Q3 '242024-09-30—$-20.18M$-0.78$-23.44M
Q2 '242024-06-30—$-17.49M$-0.68$-18.01M
Q1 '242024-03-31—$-13.31M$-0.55$-14.92M
Q4 '232023-12-31—$-12.90M$20.53$-9.35M
Q2 2025 • period ending 2025-06-30 • filed 2025-08-13
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-34.1%
ROA
-32.9%
Div Yield
—
FCF Yield
—
Debt/Equity
0.00
Current Ratio
—
Market Cap
$0.00
as of 2025-10-28
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
808.96K
SI % of Float
5.51%
Days to Cover
1.81
Short Vol Ratio
55.6%
Free Float
14.68M
Float %
57.2%
Short interest 2025-10-15 • Short volume 2025-10-27 • Float 2025-05-16